Gynecologic: Endometrial and Cervical
This session provides a comprehensive update on the contemporary management of endometrial and cervical cancers with an emphasis on recent advances that may impact radiotherapeutic management. Using a case based approach, this session reviews current risk stratification approaches, evolving treatment paradigms including the integration of molecular profiling and updated evidence guiding decisions regarding adjuvant therapy for endometrial cancer. For cervical cancer, they address key developments including the integration of immunotherapy with definitive chemoradiotherapy and advances in image guided adaptive brachytherapy and MRI based planning.
Target Audience
The meeting is designed to meet the interests of practicing radiation oncologists, radiation oncology residents, medical and clinical physicists, radiation therapists, radiation dosimetrists, nurses and all other health professionals involved in the field of radiation oncology.
Learning Objectives
Upon completion of this activity, participants should be able to do the following:
- Describe the rationale for utilization of molecular tumor testing for decision making regarding adjuvant therapy for patients with endometrial carcinoma.
- Describe the role of immunotherapy for patients with locally advanced cervical cancer.
- Describe the rationale for image guided brachytherapy and advanced brachytherapy techniques.
Moderator
- Megan Daly, MD, University of California Irvine, Chao Family Comprehensive Cancer Center
Speaker
- Lilie Lin, MD, FASTRO, University of Texas, MD Anderson Cancer Center
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Available Credit
- 1.75 AMA PRA Category 1 Credit™
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.75 Certificate of AttendanceThis activity was designated for 1.75 AMA PRA Category 1 Credit™.

Facebook
X
LinkedIn
Forward